KPTI News and Press, Karyopharm Therapeutics Inc. From 05/27/20

It should first be noted we did not consult with Epizyme, Inc. in the preparation of this article. Our analysis concludes Epizyme, Inc.'s (EPZM) is an incredible company and EPZM's product Tazverik could have a bright future treating those who suffer from Follicular Lymphoma. EPZM's Tazverik...

-- Fireside Chat Scheduled for Tuesday, June 2, 2020, at 9:30 a.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Off...

Karyopharm Therapeutics (NASDAQ: KPTI ) will host an investor conference call on May 29 at 1:00 p.m. ET, to discuss detailed results from the Phase 3 BOSTON study evaluating once-weekly XPOVIO (selinexor) in combination with once-weekly Velcade (bortezomib) and low-dose dexa...

-- Conference Call Scheduled for Friday, May 29, 2020 at 1:00 p.m. ET -- NEWTON, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it will host an investor conference call to ...

Investment Thesis Performance improvement first requires standards, then requires alternative paths to choose between. The alternatives need comparable measurements of what to expect, how likely those are to be achieved, and what it may cost when they are not. The equity reward scorecard f...

Karyopharm Therapeutics (NASDAQ: KPTI ) has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval for XPOVIO (selinexor), an oral Selective Inhibitor of Nuclear Export (SINE) compound, as a new treatment for patients with previously treated multiple myeloma. Mo...

NEWTON, Mass., May 20, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven  pharmaceutical company, today announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for XPOV...

Karyopharm Therapeutics Inc. (KPTI) is a commercial pharmaceutical company focused on drugs/therapies directed against nuclear transport and related targets for the treatment of cancer and other major diseases. KPTI employs approximately 350 people out of their Newton, MA headquarters. The com...

NEWTON, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced a new initiative to donate and distribute 60,000 medical masks to some of the most vulnerable individuals impacted by the ongoing COVID-19...

NEWTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an innovation-driven pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Health...